| Catalog Number |
PR57149072 |
| CAS |
57149-07-2 |
| Structure |  |
| Description |
Naftopidil has been investigated for the treatment of Disorder of Urinary Stent. |
| Synonyms |
Flivas; KT-611; Naftopidil [INN]; Avishot |
| IUPAC Name |
1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol |
| Molecular Weight |
392.5 |
| Molecular Formula |
C24H28N2O3 |
| InChI |
HRRBJVNMSRJFHQ-UHFFFAOYSA-N |
| InChI Key |
InChI=1S/C24H28N2O3/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23/h2-12,20,27H,13-18H2,1H3 |
| Drug Categories |
Adrenergic Agents; Adrenergic alpha-Antagonists; Adrenergic Antagonists; Agents causing hyperkalemia; Agents that produce hypertension; Antiarrhythmic agents; Antihypertensive Agents; Antiplatelet agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cardiovascular Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Hematologic Agents; Membrane Transport Modulators; Neurotransmitter Agents; Vasodilating Agents |
| Drug Interactions |
Abaloparatide-Abaloparatide may increase the hypotensive activities of Naftopidil.
Abametapir-The serum concentration of Naftopidil can be increased when it is combined with Abametapir.
Abciximab-The risk or severity of bleeding can be increased when Naftopidil is combined with Abciximab.
Abrocitinib-The risk or severity of bleeding and thrombocytopenia can be increased when Naftopidil is combined with Abrocitinib.
Acarbose-The risk or severity of hypoglycemia can be increased when Naftopidil is combined with Acarbose. |
| Isomeric SMILES |
COC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC=CC4=CC=CC=C43)O |
| Type |
Small Molecule |
| Therapeutic Category |
Urinary System Drugs |
It should be noted that our service is only used for research, not for clinical use.
